2nd May 2018

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,


Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

Ashish Chauhan
Senior Manager – Corporate Secretarial

Encl: as above
Cipla Receives Final Approval for Generic Vazculep®,
Generic Phenylephrine Hydrochloride Injection USP, 10 mg/mL Single-Dose Vial and Generic Aromasin®

India, Mumbai, May 02, 2018: Cipla Limited, a global pharmaceutical company, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Phenylephrine Hydrochloride Injection USP, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Pharmacy Bulk Package, Phenylephrine Hydrochloride Injection USP, 10 mg/mL Single-Dose Vial and Exemestane Tablets, 25mg from the United States Food and Drug Administration (USFDA).

Phenylephrine Hydrochloride Injection USP, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Pharmacy Bulk Package, is an AP-rated generic equivalent of Avadel’s Vazculep®, and is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. The product will be available for shipping in the near future.

Cipla’s Phenylephrine Hydrochloride Injection USP, 10 mg/mL Single-Dose Vial, is an AP-rated generic equivalent of West Ward Pharm Corp’s Phenylephrine Hydrochloride Injection, 10 mg/mL, and is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in such settings as septic shock or anesthesia. The product will be available for shipping in the near future.

Cipla’s Exemestane Tablets, 25mg, is an AB-rated generic equivalent of Pfizer’s Aromasin®, and is indicated for treatment of certain types of breast cancer in postmenopausal women. The product will be available for shipping in the near future.

Vazculep® and generic equivalents had U.S. sales of approximately $56M for the 12-month period ending February 2018, according to IQVIA (IMS) Health. Aromasin® and generic equivalents had U.S. sales of approximately $77M for the 12-month period ending February 2018, according to IMS Health.

The products are manufactured at the company’s Goa plant.

About Cipla Ltd.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla’s research and development focuses on developing innovative products and drug delivery systems.

**Media Contacts:**

**Corporate Communications**

Pallavi Golar

E-Mail: pallavi.golar@cipla.com

**Investor Relations**

Naveen Bansal

E-Mail: Investor.Relations@cipla.com